Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats: Effect of exendin-4 on peripheral nerves
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Glucagon-like peptide-1 (GLP-1) receptors are widely expressed in neural tissues and diminish neuronal degeneration or induce neuronal differentiation. The aim of this study was to investigate the effect of the GLP-1 pathway on peripheral nerves in streptozotocin-induced diabetic rats. EXPERIMENTAL APPROACH: Diabetic and nondiabetic rats were treated with the GLP-1 receptor agonist, synthetic exendin-4 (i.p., 1 nmol·kg(-1)·day(-1)) or placebo for 24 weeks, and current perception threshold values, cAMP levels and nerve fibre size in the sciatic nerve were measured. We also investigated GLP-1 receptor expression, quantitative changes in PGP9.5-positive intraepidermal nerve fibres and cleaved caspase 3-stained Schwann cells by immunohistochemistry. KEY RESULTS: GLP-1 receptor expression was detected in the sciatic nerve and skin. After exendin-4 treatment, the increase seen in current perception threshold values at 2000 and 250 Hz in diabetic rats was reduced. Also, the decrease in myelinated fibre size or axon/fibre area ratio in the sciatic nerve and the loss of intraepidermal nerve fibre in the skin of diabetic rats were ameliorated. These responses were closely associated with the attenuation of Schwann cell apoptosis and improvement in the cAMP level in exendin-4-treated diabetic rats, compared with placebo-treated animals. CONCLUSION AND IMPLICATIONS: Synthetic exendin-4 may prevent peripheral nerve degeneration induced by diabetes in an animal model, supporting the hypothesis that GLP-1 may be useful in peripheral neuropathy. The neuroprotection is probably attributable to GLP-1 receptor activation, antiapoptotic effects and restoration of cAMP content.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 2×
“GLP-1 and a receptor agonist offer protective effects in neuronal cells in addition to in insulinsecreting cells, by coupling to trophic and antiapoptotic signalling pathways (Perry et al., 2002a; 2003; Li et al., 2003).”
BackgroundLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 2×
“…also retarded neuron degeneration and stimulated cell proliferation by attenuating the toxicity of amyloid-b and oxidative challenge, findings that reinforce the potential value of incretins in treating Parkinson’s disease and Alzheimer’s disease (Perry et al., 2003; Li et al., 2009a,b; 2010).”
BackgroundGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“GLP-1 receptors are expressed widely in the central and peripheral nervous systems, and evidence is accumulating that they are active (Goke et al., 1995; Nakagawa et al., 2004).”
BackgroundProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 3×
“Similar to other neurotrophins, the neurotrophic functions of GLP-1 and exendin-4 are identified through modulation of neuronal cell survival (Perry et al., 2002a; Perry and Greig, 2003).”
BackgroundResultVahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · cited 2×
“Previous studies demonstrated that the GLP-1 receptor was found in peripheral neurons of male rats and in the epidermis or hair follicles of newborn mice (Nakagawa et al., 2004; List et al., 2006; Vahl et al., 2007).”
ResultDrucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274
Park, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070778 · Cited by 218 · cited 4×
“…GLP-1 receptor, treatments with 1 nmol·kg-1 exendin-4 and 0.05 mg·kg-1 exendin-4 analog (E4a) are reported to ameliorate diabetic nephropathy and retinopathy, two microvascular complications that are commonly found in diabetes along with diabetic neuropathy (Park et al., 2007; Zhang et al., 2009).”
BackgroundInfluentialRother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Cited by
The role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87
Kamiya, M., Mizoguchi, F., & Yasuda, S. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13025 · Cited by 49
Metadata
- Authors
- Liu, W. J., Jin, H. Y., Lee, K. A., Xie, S. H., Baek, H. S., & Park, T. S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-10-11
- Volume
- 164
- Issue
- 5
- Pages
- 1410-1420
- ISSN
- 0007-1188 (ISSN-L)
- OpenAlex
- W1510325212
- Cited by
- 84
- References
- 10
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats: Effect of exendin-4 on peripheral nerves. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01272.x
- The paper
- Liu, W. J., Jin, H. Y., Lee, K. A., Xie, S. H., Baek, H. S., & Park, T. S. (2011). Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats: Effect of exendin-4 on peripheral nerves. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01272.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.